MannKind welcomes Jennifer Grancio to its Board of Directors

– USA, CA –  MannKind Corporation (NASDAQ: MNKD | TASE: MNKD) today announced the appointment of Jennifer Grancio to its Board of Directors, effective March 23, 2020, and will also serve as a member of the Audit Committee of the Board.

Ms. Grancio brings to MannKind over twenty years of financial services experience and expertise in creating disruptive business models.

“We are excited to welcome Ms. Grancio and her years of invaluable leadership to our board of directors,” said Kent Kresa, Chairman. “Her financial services leadership experience will be an essential asset for MannKind as the company continues to grow. We are committed to surrounding ourselves with the best talent available, and the appointment of Ms. Grancio reflects that effort.”

With the addition of Ms. Grancio, there are nine members of the MannKind Board of Directors.

About Jennifer Grancio

Ms. Grancio served as a founder and executive with BlackRock’s iShares business from 1999 to 2018. She spearheaded the distribution of iShares in the United States and Europe and acted as the Global Head of Marketing and Partnerships for BlackRock’s indexing service. Through those efforts, Ms. Grancio established herself as a global leader in exchange-traded and mutual funds.

Since her time at BlackRock, she founded Grancio Capital, where she consults with company leaders on the best ways to expand market reach and how to build effective teams to do so. Previously, she was a senior associate with PricewaterhouseCoopers, a management consulting firm.

Ms. Grancio has served as a board member for Ethic, a sustainable investing firm, since November 2019. She serves on the board of Harvest Savings & Wealth as of Q1 2020 and is on the advisory boards of Say Technologies and m+ funds. Ms. Grancio is also active as a strategic advisor and speaker to organizations that are committed to developing diverse senior leaders and to developing leadership in young women.

She earned a bachelor’s degree in economics and international relations from Stanford University, and an MBA degree in strategy and finance from Columbia Business School.

About MannKind Corporation

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the-art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>